Phase II clinical trials are concerned with making decision of whether a treatment is sufficiently efficacious to be worth further investigations in late large scale Phase III trials. In oncology Phase II trials, frequentist single-arm two-stage groupsequential designs with a binary endpoint are commonly used. To allow for more flexibility, adaptive versions of these designs have been proposed. In this paper, we propose point and interval estimation for adaptive designs in which the second stage sample size is a pre-specified function of first stage's number of responses. Our approach is based on sample space orderings, from which we derive p-values, and point and interval estimates. Simulation studies show that our proposed methods perform better, in terms of bias and root mean square error, than the fixed-sample maximum likelihood estimator.
Introduction
Phase II trials are concerned with making decision of whether a treatment is sufficiently efficacious to justify its further investigations in late large scale Phase III trials. In oncology Phase II trials, frequentist single-arm twostage group-sequential designs with binary endpoints are commonly used. Based on ethical desirability to expose less patients to an inefficient treatment and to speed-up the development process, these designs allow early termination of the trial for futility and/or efficiency (e.g., designs by Schultz et al. 1 and Simon 2 ). In such designs, the sample sizes and decision rules for each stage are predefined. To allow flexibility, adaptive versions of these designs have been proposed. [3] [4] [5] [6] [7] [8] [9] [10] Adaptive designs allow for modification of the trial at interim analysis using the trial's accumulating data and/or external information without jeopardising trial's integrity and validity.
Although the main goal of oncology Phase II trials is hypothesis testing, estimation of the efficacy parameter after such trials remains important, especially in cases where the treatment was deemed successful since it will be needed for planning Phase III trials. In group-sequential designs (GSD), due to the possibility of early stopping for either futility or efficacy, the fixed-sample maximum likelihood estimator (MLE) of the treatment effect (response probability) is no longer unbiased. This issue has been acknowledged by many authors, and alternative estimation methods have been proposed in the literature. [11] [12] [13] [14] [15] [16] [17] [18] [19] However, most of the estimation methods for GSD are not applicable to adaptive designs. Unfortunately, the literature on estimation in adaptive GSD is mainly on Phase III clinical trials. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] To the best of our knowledge, estimation in oncology Phase II adaptive single-arm GSD with a binary endpoint has only been discussed recently by Kunzmann and Kieser, 36 who proposed a point estimator that can be interpreted as a constrained posterior mean estimate based on the non-informative Jeffreys prior. Their method is computationally intensive, and they have implemented it in the Julia 37 programming language using the JuMP 38 package and the Julia interface 38 to the commercial solver Gurobi.
of responses. However, some of the approaches that we propose can be extended to flexible designs. The procedure uses the concept of stage-wise ordering, and it is less computationally intensive and can readily be implemented in the statistical programming language R. 40 We first propose and discuss different approaches for defining sample space orderings, from which we derive p-values and then interval and point estimates. We also present the results from a simulation study to evaluate the performance of the proposed methods. The paper is organised as follows. We first give an overview of the adaptive designs for which we are developing the proposed methods. Afterwards we give the methodological details of our proposals, an illustrative example, then the results of the simulation study and we end with conclusions and a discussion.
Adaptive phase II oncology designs
We build our methodology for two-stage adaptive phase II oncology designs with binary endpoint and a prespecified adaptation rule, like those proposed by Englert and Kieser 8 and Shan et al. 9 These designs extend the classical binary endpoint oncology Phase II GSD by allowing the sample size of second stage to depend on the number of responses observed in the first stage. Like their classical GSD counterparts they test, at type I error rate and type II error rate , the null (H 0 ) versus the alternative (H 1 ) hypothesis about the response rate ()
where 0 is the maximum response rate considered to be uninteresting and 1 is the minimum desirable response rate, with 1 4 0 .
The designs we consider in this paper are defined by the first stage sample size, n 1 , futility and efficacy boundaries, l 1 and u 1 (u 1 4 l 1 ), which are fixed, and the second stage sample size, n 2 ðx 1 Þ, which depends on the number of responses observed in the first stage, x 1 . We further have the conditional error function, Dðx 1 Þ, and the corresponding decision boundary, l ðx 1 Þ, which are also functions of x 1 . The final (second) stage efficacy boundary uðx 1 Þ is set to uðx 1 Þ ¼ l ðx 1 Þ þ 1, with l ðx 1 Þ being the futility boundary. Dðx 1 Þ defines for each possible number of responses in the first stage, x 1 2 f0, . . . , n 1 g, the conditional type I error rate to be used in the second stage. 6 At the interim analysis, the trial is stopped with failure to reject H 0 if x 1 l 1 or with rejection of H 0 if x 1 ! u 1 . Otherwise the trial proceeds to the second (final) stage, after which H 0 is rejected if p 2 5 Dðx 1 Þ or, equivalently, x 4 l ðx 1 Þ, where p 2 is the second stage p-value and x is the total number of responses (i.e. x is the sum of x 1 and the number of responses observed in the second stage, x 2 ). Note that x 4 l ðx 1 Þ is equivalent to x ! uðx 1 Þ. An example of such designs is given in Table 1 .
Note that the discrete conditional error function Dðx 1 Þ in Table 1 is non-decreasing in x 1 , and takes values within ½0, 1. We assume these two properties throughout the paper. It is clear that in these designs the first stage decision boundaries are 
where Bðx, n, Þ is the binomial cumulative distribution function (c.d.f) with x successes, n trials and success probability . 
Alternative sample space orderings
To overcome this inconsistency, we propose alternative sample space orderings that take into account the conditional error function and adaptation rule. When both outcomes are from trials that continued to the second stage (i.e. m 0 ¼ m ¼ 2), we compare them taking into account their respective rejection boundaries. We accomplish this by defining a function ðx 1 , x 2 Þ that in some way incorporates the rejection boundary of the trial outcome. In all other cases, the proposed sample space orderings are similar to the stage-wise ordering discussed above. Then we have that ðm 0 , x We propose three different methods to define ðx 1 , x 2 Þ. The first two quantify the deviation between x and l ðx 1 Þ. In the first method, we define ðx 1 , x 2 Þ using directly x as
and in the second we define ðx 1 , x 2 Þ using the second stage p-value as
In both methods, is defined such that it equals to a constant when the outcome is at the decision boundary (i.e. when The two ways of defining the function above are strictly linked to the design's decision rules, and therefore require trials to strictly follow the design. We will see later that Method 2 yields valid p-values even if the adaptation rule is not strictly adhered to. One way to allow for flexibility is to order the outcomes using combination functions from adaptive tests. Combination functions combine the first and the second stage p-values, with the assumption that the data from the two stages are from independent cohorts of patients. An extensive discussion on adaptive combination tests can be found in Wassmer and Brannath. 46 The idea is to define a combination function Cð p 1 , 
Even though the Phase II designs we are dealing with might not be based on a combination function C, we can build an ordering based on C that is consistent with the rejection region given by the function D (or equivalently given by the function l). To this end, we define the C's corresponding conditional error function
and then calculate the backwards image p 1b such that Að p 1b Þ ¼ Dðx 1 Þ, where Dðx 1 Þ is the conditional error of the original design.
A natural and common choice for Cð p 1 , p 2 Þ is the weighted inverse normal combination function, 51 which can be represented as 46 
Cð p
where È is standard normal c.d.f., and w 1 and w 2 are predefined weights chosen such that w
Here we propose to use weights that give more emphasis to the stage with higher sample size, i.e.
The conditional error function of the inverse normal combination function is
We finally define as
With defined in this way, the condition ðx 2 Þ Cð p 1b , p 2 Þ, meaning that the outcome with lower Cð p 1b , p 2 Þ is considered to be more extreme.
Another possible sample space ordering could be to simply order the trial outcomes by the proportion of responses, i.e. ðx 1 þ x 2 Þ=½n 1 þ n 2 ðx 1 Þ. However, this ordering would not always be consistent with the design's decision rule because in some designs the ratio of the final decision boundary and the total sample size, i.e. l ðx 1 Þ=½n 1 þ n 2 ðx 1 Þ, might not be constant. 
Overall p-value
We use the sample space ordering proposed in the previous section to derive an overall p-value, denoted by Q, meant to be calculated when the trial has been terminated. Q is defined as the probability of observing under H 0 an outcome ðm 0 , x 0 1 , x 0 Þ that is similar or more extreme than the outcome ðm, x 1 , xÞ actually observed in the trial. If the observed outcome is from a trial that stopped at the first stage, outcomes with x 0 1 ! x 1 are more extreme, irrespective of their stopping stage, implying the overall p-value
If the observed outcome is from a trial that continued to the second stage, more extreme are outcomes from trials that stopped at the first stage with x 0 1 ! u 1 or continued to the second stage with ðx
Since X 1 and X 2 follow binomial distribution, we can write the overall p-value as
where bðx, n, Þ is the binomial probability mass function with x successes, n trials and success probability ,
We discuss in the following lines approaches to calculate the probability of ðX 1 , (1), since we are working directly with the number of events (responses), this probability can easily be calculated as (we call this Method 1)
For the other two methods, we use approximations. We make use of the fact that a p-value P is in general stochastically not smaller than a standard uniform variate, i.e. Assuming that the first stage design is pre-fixed and is strictly followed, and that the first and the second stage data are from independent cohorts of patients, using the second stage p-value p 2 as the test statistic guarantees the conditional invariance principle. 46 Conditional on the first stage data and second stage design, the distribution of p 2 under H 0 is not smaller than the uniform distribution. This implies that the type I error rate is controlled irrespective of the adaptation rule.
When using the ðx 1 , x 2 Þ in (2) (Method 2), we approximate Pr 0 Á ! ð Þas
where
Another
Finally, using the ðx 1 , x 2 Þ in (3), Method 3, we have that
See more details in Appendix 1.
Point and interval estimation
We follow the approach discussed in Chapter 8 of Wassmer and Brannath. 46 Exploiting the duality between confidence intervals (CI) and hypothesis tests, we construct the CI by considering all the null hypotheses The confidence set is a collection of 0 for which H 0 is not rejected. Assuming that the overall p-value Q is monotone increasing in 0 for all outcomes ðm, x 1 , xÞ, the region 0 :
where the lower bound
L is the solution, in 0 , of the equation Qð 0 Þ ¼ .
As the point estimate we take the lower bound of the 50% one-sided CI, i.e. ¼
0:5
L , which is an approximate median unbiased estimator. Similar estimators have been proposed for classical oncology two-stage GSDs by Koyama and Chen 14 and Jovic and Whitehead, 18 which are applicable only if n 2 is a constant for all x 1 . There are four different methods (Method 1, Method 2, Method 2v2 and Method 3) for calculating the overall p-value Q (see the previous section) on which the estimation approach is based, resulting, therefore, in four different estimates. We name these estimates after their respective p-value calculation methods, to make a distinction amongst them throughout the rest of this paper. Table 2 lists the methods together with the function used in sample space ordering, the way Pr 0 Á ! jx 0 1 À Á (part of Q that differ across the methods) is estimated, and the implications for estimation.
As mentioned before, in order to this estimation technique to work, it is necessary that the overall p-value Q as function of response probability be monotone increasing for 2 ½0, 1. We checked the monotonicity of QðÞ numerically for all 34 designs listed in Englert and Kieser, 8 for all possible outcomes and ranging from 0 to 1 by increments of 0.01. We found that Methods 2 and 3 are monotone in all designs. Method 1 is monotone, except for four designs when ! 0:8. In the case of non-monotonicity, a conservative solution may be found using the cumulative maximum of QðÞ, i.e. Q cm ðÞ ¼ maxfQð 0 Þ : 0 g. We give more details on how the estimation is done for each of the three methods in Appendix 1.
Illustrative example
Suppose that a Phase II trial testing the activity of an anti-cancer agent was conducted using the design given in Table 1 . Suppose further that at the interim analysis it was found that 8 out of 20 patients responded to the treatment, leading to the decision to proceed with the trial to the second (final) stage. Therefore, 39 additional patients were recruited and treated, of which 18 were responsive. With a total of 26 responders out of 59 patients at the end of trial, the decision according to the design's decision rule was to reject the null. Calculating the overall p-value using the proposed approach, methods 1, 2, 2v2 and 3, we get the values 0.00261, 0.00360, 0.00315 and 0.00261, respectively. As it can be seen, all the p-values are less than the significance level ¼ 0:05, meaning that with the proposed methods we also reject the null hypothesis. With the null hypothesis rejected, one would be interested in getting the response rate estimate to possibly use it for planing further trials. If we would ignore the adaptive nature of the design and employ the fixed-sample maximum likelihood estimator, the point estimate would be 0.44068. The point estimates obtained using the proposed approach are 0.42264, 0.41367, 0.41337 and 0.41411, respectively, for the methods 1, 2, 2v2 and 3. The corresponding 95% one-sided CIs are 0:29561; 1, 0:29105; 1, 0:27918; 1 and 0:29379; 1.
Numerical study
We did an extensive numerical study to evaluate various aspects of the proposed methods. We computed, for all designs in Englert and Kieser, 8 the overall p-value to see how it behaves for the three methods, as well as to check whether it is consistent with the original decision rule. The computation was for all possible outcomes, with values of 0 varying from 0 to 1 by 0.01 for each. We then did a simulation study to assess the performance of the proposed estimator using the three methods. The performance of the point estimate was quantified in terms of bias and root mean square error (RMSE), and the performance of the interval estimate was quantified by the coverage probability and mean of the lower bound. We calculated, in addition, the type I error and power using the original decision rule and using the overall p-value from the proposed methods.
Bias was defined as 1 T P T t¼1 t À ð Þ and RMSE as the square root of
where T is the total number of simulated trials, the estimated response probability and the response probability under which trials were simulated. The coverage probability was computed as the proportion of trials in which the ð1 À Þ100% CI contained the true response rate , i.e., proportion of trials in which the lower bound of the CI is less than . The type I error was calculated as the proportion of trials simulated under ¼ 0 in which H 0 was rejected, and the power calculated similarly but for trials simulated under ¼ 1 .
For comparison purposes, we included the maximum likelihood estimator (MLE) for fixed-sample designs, which we believe is more likely to be employed when analysing data from adaptive designs for which no specific Table 2 . Methods for calculating the overall p-value Q.
Method
Pr 0 Á ! jx0 1 ð Þ Implications for estimation
Note: denotes the function used for sample space ordering and P r 0 Á ! jx 0 1 À Á is the part of the Q formula that vary across the methods. In the ''Implications for estimation,'' Exact means the resulting point and interval estimates are obtained using exact probability calculations, while Approximate means approximations are used, i.e. the estimation is based on continuous uniform distribution of second stage p-value.
estimation methods are available. When applying this estimator, we ignored the adaptive nature of the design and we did estimation as if the data were from a fixed-sample (single-stage) design. Therefore, the MLE is the sample proportion of the pooled data. We didn't include the estimators proposed for classical GSDs mentioned above. Their formulae are based on the fact that the second stage sample size is pre-defined and constant, therefore, they would not be applicable here without modification. We used two versions of MLE, one that uses all trial data, p ¼ ½x 1 þ x 2 =½n 1 þ n 2 ðx 1 Þ, and the other that uses the first stage data only, p1 ¼ x 1 =n 1 . The reason for includinĝ p1 is that since it is unbiased, it will serve as benchmark for comparison with respect to RMSE, i.e. a new estimator would not be desirable if it would be outperformed by p1 in terms of RMSE. We denote the estimated response probability by m1 for Method 1, m2 for Method 2, m2v2 for Method 2v2, and m3 for Method 3. The simulation were done for two designs of Englert and Kieser, 8 one with a moderate 1 , ð 0 , 1 , , , n 1 Þ ¼ ð0:2, 0:4, 0:05, 0:1, 20Þ, we call this design 1, and the other (design 2) with relatively high 1 , ð 0 , 1 , , , n 1 Þ ¼ ð0:4, 0:6, 0:05, 0:1, 22Þ. For both designs we varied, in the simulated trials, the true response probability from 0 to 1 by increments of 0.01. For each scenario, 50,000 simulations were run.
We implemented all the methodology described above in the statistical programming language R. 40 The code and datasets containing all designs listed in Englert and Kieser 8 are available from the authors upon request. Figure 1 shows plots of overall p-value for all possible values of x when x 1 ¼ 8 and x 1 ¼ 11 in designs 1 and 2, respectively. It can be seen that, as expected, all methods are consistent with design's decision rule. Results from simulation study in Table 3 reveal that type I error rate and power of Methods 1 and 2v2 are equal to those of design's original decision rule, which are in turn very close to the nominal levels. Methods 2 and 3 are conservative, as their type I error rate is lower compared to other methods. Simulation results on bias and RMSE of the estimators for values of ranging from 0 to 1 are shown in Figures 2 and 3 , respectively. Table 4 shows the results of simulations under H 1 ( ¼ 1 ), and, in addition to bias and RMSE, it shows the mean and the first, second and third quartiles of the estimates, and the coverage probability and the mean lower bound of the one-sided ð1 À Þ100% CI. The same results for simulations under ¼ 1 þ 0:1 are shown in Table 5 . The behaviour of the estimators change depending on whether the true response rate () is close to or far from the hypothesised one ( 1 ). Taking a closer look at Figure 2 we can see that, except the first stage sample proportion ( p1 ) which is unbiased as expected, all estimators are negatively mean biased for values of around 0 . When the true response rate is close to 1 , the estimators of the proposed methods ( m1 , m2 , m2v2 and m3 ) are almost unbiased, while the fixed sample MLE ( p ) shows positive bias. As approaches 1, the proposed estimators become more and more negatively biased, while the bias of p approaches 0. Among the proposed estimators, m2v2 behaves slightly different, as moves from 0 to 1, it is the first to attain mean bias that is closest to zero, which happens just after 1 . Regarding RMSE (see Figure 3) , the proposed estimators also outperform p for values of around 1 . Their RMSE is also lower than that of p1 . From Table 4 we see that under H 1 the simulation mean and median are similar, and they are relatively lower in the proposed estimator as compared to p . The one-sided CIs have good coverage probabilities for all the proposed methods, with values that are not less than the nominal level (95%). The mean of the lower bound of CIs are similar across the proposed methods. The simulation done assuming ¼ 1 þ 0:1 (Table 5) showed similar results.
Results

Discussion
In this paper, we have discussed and proposed sample space orderings for oncology Phase II adaptive two-stage designs with binary endpoint. Overall p-value and point and interval estimation were derived from these sample space orderings. Although for some values of true response probability our methods do not show improvement over the fixed sample MLE, they are preferable because they consistently outperform the MLE when the true response probability is in the neighbourhood of values that are equal to or greater than the response probability under the alternative hypothesis. It is in this region where the estimation becomes particularly important since the null hypothesis would likely have been rejected and the treatment effect estimate needed to plan later Phase III trials. In this region, the MLE shows high positive bias and higher RMSE while our methods are either unbiased or negatively biased with smaller RMSE.
In general, as opposed to the fixed sample MLE, our proposed methods do not overestimate the response probability. This is seen by the fact that for values of true response rate raging from 0 to 1, they are either unbiased or negatively biased. Overestimation of treatment effect in Phase II trials has been acknowledged in the literature as one of the reasons for high failure rate of drugs in Phase III. For example, Kirby et al. 52 showed an evidence that supports the need to, and proposed methods to, discount the Phase II estimate of treatment effect when it is used to plan Phase III trial sample size.
Although our methods were built on top of Englert and Kieser 8 design, they can easily be extended to other similar designs with pre-specified adaptation rules. One example are the adaptive designs by Shan et al. 9, 10 Further, some of our proposed approaches (methods 2 and 3) remain valid even if the adaptation rule is not pre-specified, meaning that they can be applied for flexible designs. Methods 2 and 3 can be extended to handle non-binary outcomes, while with the Method 1, that uses exact probability calculation, an extension would be difficult.
Note that some of steps above are only valid because È is a continuous and monotone increasing function.
Details on point and interval estimation
Let 0 be the response probability under the design's original null hypothesis H 0 , and we denote by 0 the response probability under all null hypotheses we consider when searching for point and interval estimates, with 0 0 1. Then the overall p-value to search for the estimates is defined as 
